Enlivex – a Hadasit start-up company (under HBL) which develops a preventive immune-modulatory treatment invented by Prof. Dror Mevorach and his laboratory at Hadassah Medical Center – has successfully completed the first Phase I/IIa clinical trial for testing the safety and preliminary assessment of the effectiveness of ApoCell in the prevention and treatment of graft-versus-host disease (GVHD), a devastating and potentially life-threatening complication that occurs in 50-70% of patients receiving bone-marrow transplantation.

The innovative treatment is meant to reduce the life-threatening complications of bone marrow transplantation. The clinical trial was conducted at three hospitals in Israel (Hadassah Ein Kerem, Rambam and Sheba) and included 13 patients at the first stage.

Due to the successful conclusion of the first clinical study, the company will expand the trial to additional patients in order to establish a leading preventive treatment for the GVHD.